Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious OutperformanceFind Stocks Now

China gave COVID-19 vaccine candidate to North Korea's Kim: U.S. analyst

Published 11/30/2020, 07:40 PM
Updated 12/01/2020, 04:55 AM
© Reuters. Emergency meeting of Political Bureau of WPK Central Committee

(This story corrects identity and removes RIC of third company listed in para 5 to China Pharmaceutical Group (Sinopharm), and in para 6 corrects to show Phase 3 trials being conducted outside China)

By Hyonhee Shin

SEOUL (Reuters) - China has provided North Korean leader Kim Jong Un and his family with an experimental coronavirus vaccine, a U.S. analyst said on Tuesday, citing two unidentified Japanese intelligence sources.

Harry Kazianis, a North Korea expert at the Center for the National Interest think tank in Washington, said the Kims and several senior North Korean officials had been vaccinated.

It was unclear which company had supplied its drug candidate to the Kims and whether it had proven to be safe, he added.

"Kim Jong Un and multiple other high-ranking officials within the Kim family and leadership network have been vaccinated for coronavirus within the last two to three weeks thanks to a vaccine candidate supplied by the Chinese government," Kazianis wrote in an article for online outlet 19FortyFive.

Citing U.S. medical scientist Peter J. Hotez, he said at least three Chinese companies were developing a coronavirus vaccine, including Sinovac Biotech Ltd, CanSinoBio and China National Pharmaceutical Group (Sinopharm), an unlisted Beijing-based company.

Sinopharm says its candidate has been used by nearly one million people in China, although none of the firms have unveiled results of Phase 3 clinical trial of their experimental COVID-19 vaccines, which are under way outside China.

Some experts doubted that Kim would use an experimental vaccine.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

"Even if a Chinese vaccine had already been approved, no drug is perfect and he would not take that risk when he has numerous shelters which can ensure almost complete isolation," said Choi Jung-hun, an infectious disease expert who defected from North Korea to the South in 2012.

Mark Barry, an East Asia analyst and associate editor of the International Journal on World Peace, said Kim would prefer proven European vaccines to one supplied by Beijing.

"The risk is too great. But he's happy to get Chinese personal protective equipment," Barry said on Twitter.

North Korea has not confirmed any coronavirus infections, but South Korea's National Intelligence Service (NIS) has said an outbreak there cannot be ruled out as the country had trade and people-to-people exchanges with China - the source of the pandemic - before shutting the border in late January.

Microsoft (NASDAQ:MSFT) said last month that two North Korean hacking groups had tried to break into the network of vaccine developers in multiple countries, without specifying the companies targeted. Sources told Reuters they included British drugmaker AstraZeneca (NASDAQ:AZN).

The NIS said last week it had foiled North Korea's attempts to hack into South Korean COVID-19 vaccine makers.

Latest comments

North korean expert meanwhile he has never set foot in North Korea before
why not give the vaccine formulation to them. it's not likely anyone will make money on the transfere anyway. Why let the regular people in NK die. That's just spiteful.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.